title: Telenzepine-sensitive muscarinic receptors on rat pancreatic acinar cells.
abstract: To identify the muscarinic subtype present on the rat pancreatic acinar cell, we examined the effects of different muscarinic receptor antagonists on amylase secretion and proteolytic zymogen processing in isolated rat pancreatic acini. Maximal zymogen processing required a concentration of carbachol 10- to 100-fold greater (10(-3) M) than that required for maximal amylase secretion (10(-5) M). Although both secretion and conversion were inhibited by the M3 antagonist 4-diphenylacetoxy-N-methyl-piperidine (4-DAMP) (50% inhibition approximately 6 x 10(-7) M and 1 x 10(-8) M, respectively), the most potent inhibitor was the M1 antagonist telenzepine (50% inhibition approximately 5 x 10(-10) M and 1 x 10(-11) M, respectively). Pirenzepine, another M1 antagonist, and the M2 antagonist methoctramine did not reduce amylase secretion or zymogen processing in concentrations up to 1 x 10(-5) M. Analysis of acinar cell muscarinic receptor by PCR revealed expression of both m1 and m3 subtypes. The pancreatic acinar cell has a distinct pattern of muscarinic antagonist sensitivity (telenzepine >> 4-DAMP > pirenzepine) with respect to both amylase secretion and zymogen conversion.
authors.affiliation: Department of Surgery, Connecticut Health Care Department of Veterans Affairs, West Haven, USA.
authors.forename: S W
authors.initials: SW
authors.lastname: Schmid
authors.forename: I M
authors.initials: IM
authors.lastname: Modlin
authors.forename: L H
authors.initials: LH
authors.lastname: Tang
authors.forename: A
authors.initials: A
authors.lastname: Stoch
authors.forename: S
authors.initials: S
authors.lastname: Rhee
authors.forename: M H
authors.initials: MH
authors.lastname: Nathanson
authors.forename: G A
authors.initials: GA
authors.lastname: Scheele
authors.forename: F S
authors.initials: FS
authors.lastname: Gorelick
mesh_terms: D000818:Animals; D015139:Blotting, Southern; D002217:Carbachol / Q000494:pharmacology; D018680:Cholinergic Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004792:Enzyme Precursors / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D010179:Pancreas / Q000166:cytology / Q000378:metabolism*; D010276:Parasympatholytics / Q000494:pharmacology*; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism*; D013997:Time Factors
chemical_list: D018680:Cholinergic Antagonists; D004792:Enzyme Precursors; D010276:Parasympatholytics; D011976:Receptors, Muscarinic; C046338:telenzepine; D010890:Pirenzepine; D002217:Carbachol